Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adaptive Biotechnologies has signed immunological biomarker discovery partnership with Bristol-Myers Squibb in the field of oncology.
Subscribe to our email newsletter
The collaboration will leverage Adaptive’s immunoSEQ immune profiling assay for the identification of potential biomarkers that may inform about drug response against oncology.
Adaptive Biotechnologies CEO and founder Chad Robins said the collaboration will help discover immunological biomarkers of response to cancer agents.
"Collaborating with Bristol-Myers Squibb is a real win for companies like ours that are committed to deepening the understanding of the interaction between the host immune system and the cancer cells themselves," Robins added.
Throughput next-generation sequencing used in the immunoSEQ assay characterizes repertoire of T and B cell receptors.
The technology aids in exploring cells of cancer patients, assessing the treatment impact on the immune system and finding patients with more chances of responding to the treatments.